The limited responses to ICB in patients with cancer, including those with B cell lymphoma and melanoma, are largely attributed to the lack of IFNγ production required for the activation of CD8+ T cells.4 The gene discussed is CD8A; the disease is B-cell non-Hodgkin lymphoma.